STAT Plus: Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is notably modest this time around. We plan to catch up on a thick pile of reading, take a few naps, and perhaps binge-watch a show on the telly, a rare indulgence. And what about you? The holiday season is fast approaching, but there is still time to make getaway plans. This is also an opportunity to stimulate the economy and purchase some gifts. You might consider a year-end charitable donation (but do try to avoid those that serve as piggy banks for their namesakes). Or you could simply take stock of life, such as it is. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

House Democrats passed sweeping legislation to lower prescription drug prices, marking the latest volley in a health care debate that has animated progressives, Republican lawmakers, drug makers, and the Trump administration all year, STAT explains. But the high-stakes showdown over drug prices is far from over. President Trump has vowed to veto the bill, which passed on a 230-192 vote, largely along party lines. And the Republican-controlled Senate is still considering a separate, less aggressive bipartisan drug pricing package.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case »